Comparing Healthcare Sector ETFs: VanEck Pharma vs. iShares Biotech
Investors evaluating healthcare exchange-traded funds must weigh the steady, dividend-paying focus of pharmaceutical giants against the broader, more volatile nature of biotechnology innovators.
🏛️EconomyPhoto: Motley Fool
Key points
- VanEck Pharmaceutical ETF features a concentrated basket of 26 holdings with a 1.8% dividend yield and a 0.36% expense ratio.
- iShares Biotechnology ETF provides broader exposure across 243 holdings with a 0.2% dividend yield and a 0.44% expense ratio.
- Pharmaceutical funds offer exposure to mature drugmakers involved in industry acquisitions, whereas biotech portfolios lean toward higher price volatility tied to research developments.
When selecting a healthcare-focused exchange-traded fund, market participants face a distinct choice between the concentrated, income-generating portfolio of the VanEck Pharmaceutical ETF (PPH) and the expansive, higher-volatility holdings of the iShares Biotechnology ETF (IBB). Established in 2011, the VanEck fund holds 26 assets with a heavy emphasis on major drug manufacturers. Its top positions include Eli Lilly at 23.24%, Merck & Co at 12.56%, and Novo Nordisk at 5.42%. Over the trailing 12 months, the fund distributed $2.14 per share, translating to a 1.8% yield based on its share price of roughly $119.21. Furthermore, it carries an expense ratio of 0.36%.
Conversely, the iShares Biotechnology ETF launched in 2001 and offers significantly broader diversification with 243 holdings, dedicating 87% to biotechnology and 10% to life sciences. Its major weightings feature Gilead Sciences at 8.94%, Amgen at 8.31%, and Vertex Pharmaceuticals at 7.87%. The fund paid $0.34 per share over the trailing 12 months, resulting in a 0.2% yield on its share price of approximately $213.79, while maintaining a slightly higher expense ratio of 0.44%.
The structural differences between the two funds reflect distinct risk tolerances and investment strategies. While the pharmaceutical fund provides exposure to mature companies engaging in mergers and acquisitions amid expiring patents, the biotech fund captures smaller developers whose valuations can swing dramatically on clinical trial results or buyout news.
Source Motley Fool — fool.com/coverage/etfs/2026/11/15/which-healthcare-etf-is-the-bette… ↗
Read next
🧠AI AnalysisWalmart Shares Waver Despite Topping Estimates as Growth Momentum Cools
Walmart posted third-quarter results that surpassed analyst expectations, though slower growth rates across key segments prompted market hesitation before the stock recov…
🧠AI AnalysisBitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold
Bitcoin recently traded around $59,090 following a decisive breakdown below the crucial $62,000–$64,000 support zone, shifting short-term market momentum toward sellers.
🧠AI AnalysisBitcoin Tests Support Following Drop Below $60,000 Milestone
Bitcoin recently swept the $55,000 mark before rebounding toward the $59,100 region following a sharp decline that broke previous support levels on November 20.
🧠AI AnalysisEvaluating HF Sinclair and the Turning Oil Refining Cycle
HF Sinclair has experienced impressive expansion driven largely by its refining sector, but market observers suggest the cyclical peak may be near.
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.